Antibody Response and Disease Severity in Healthcare Worker MERS Survivors
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
We studied antibody response in 9 healthcare workers in Jeddah, Saudi Arabia, who survived Middle East respiratory syndrome, by using serial ELISA and indirect immunofluorescence assay testing. Among patients who had experienced severe pneumonia, antibody was detected for >18 months after infection. Antibody longevity was more variable in patients who had experienced milder disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tang, F., Quan, Y., Xin, Z.-T., Wrammert, J., Ma, M.-J., Lv, H., Wang, T.-B., Yang, H., Richardus, J. H., Liu, W., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.0903490 · Cited by 496 · cited 2×
“Although T cells have persisted up to 6 years in SARS survivors (2), whether these patients would have been protected if infected a second time with SARS-CoV is unknown.”
BackgroundChannappanavar, R., Fett, C., Zhao, J., Meyerholz, D. K., & Perlman, S. (2014) · Journal of Virology · doi:10.1128/jvi.01505-14 · Cited by 411 · cited 4×
“Although T cells have persisted up to 6 years in SARS survivors (2), whether these patients would have been protected if infected a second time with SARS-CoV is unknown.”
BackgroundInfluential
Cited by
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.017 · Cited by 1,788
Okba, N. M. A., Müller, M. A., Li, W., Wang, C., GeurtsvanKessel, C. H., Corman, V. M., Lamers, M. M., Sikkema, R. S., de Bruin, E., Chandler, F. D., et al. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2607.200841 · Cited by 1,614
Middle East respiratory syndrome
Zumla, A., Hui, D. S., & Perlman, S. (2015) · The Lancet · doi:10.1016/s0140-6736(15)60454-8 · Cited by 1,263
Self-citationHuang, A. T., Garcia-Carreras, B., Hitchings, M. D. T., Yang, B., Katzelnick, L. C., Rattigan, S. M., Borgert, B. A., Moreno, C. A., Solomon, B. D., Trimmer-Smith, L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18450-4 · Cited by 1,026
Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses
Schmidt, F., Weisblum, Y., Muecksch, F., Hoffmann, H.-H., Michailidis, E., Lorenzi, J. C. C., Mendoza, P., Rutkowska, M., Bednarski, E., Gaebler, C., et al. (2020) · Journal of Experimental Medicine · doi:10.1084/jem.20201181 · Cited by 572
Middle East respiratory syndrome
Memish, Z. A., Perlman, S., Van Kerkhove, M. D., & Zumla, A. (2020) · The Lancet · doi:10.1016/s0140-6736(19)33221-0 · Cited by 479
Self-citationRöltgen, K., Powell, A. E., Wirz, O. F., Stevens, B. A., Hogan, C. A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M. K., Huang, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe0240 · Cited by 452
T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV
Liu, W. J., Zhao, M., Liu, K., Xu, K., Wong, G., Tan, W., & Gao, G. F. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2016.11.006 · Cited by 395
Kellam, P., & Barclay, W. (2020) · Journal of General Virology · doi:10.1099/jgv.0.001439 · Cited by 351
Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus
Fehr, A. R., Channappanavar, R., & Perlman, S. (2017) · Annual Review of Medicine · doi:10.1146/annurev-med-051215-031152 · Cited by 293
Self-citationRobust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19
Sekine, T., Perez-Potti, A., Rivera-Ballesteros, O., Strålin, K., Gorin, J.-B., Olsson, A., Llewellyn-Lacey, S., Kamal, H., Bogdanovic, G., Muschiol, S., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.06.29.174888 · Cited by 272
Recovery from the Middle East respiratory syndrome is associated with antibody and T cell responses
Zhao, J., Alshukairi, A. N., Baharoon, S. A., Ahmed, W. A., Bokhari, A. A., Nehdi, A. M., Layqah, L. A., Alghamdi, M. G., Al Gethamy, M. M., Dada, A. M., et al. (2017) · Science Immunology · doi:10.1126/sciimmunol.aan5393 · Cited by 263
Self-citationProspects for a safe COVID-19 vaccine
Haynes, B. F., Corey, L., Fernandes, P., Gilbert, P. B., Hotez, P. J., Rao, S., Santos, M. R., Schuitemaker, H., Watson, M., & Arvin, A. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abe0948 · Cited by 261
Serological Approaches for COVID-19: Epidemiologic Perspective on Surveillance and Control
Lee, C. Y.-P., Lin, R. T. P., Renia, L., & Ng, L. F. P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00879 · Cited by 260
MERS-CoV Antibody Responses 1 Year after Symptom Onset, South Korea, 2015
Choe, P. G., Perera, R. A. P. M., Park, W. B., Song, K.-H., Bang, J. H., Kim, E. S., Kim, H. B., Ko, L. W. R., Park, S. W., Kim, N.-J., et al. (2017) · Emerging Infectious Diseases · doi:10.3201/eid2307.170310 · Cited by 227
“In a study in Saudi Arabia, 9 patients with RT-PCR– confirmed MERS-CoV infection were followed up at 3 months, 10 months, and 18 months (for only 2 patients) after infection and tested by MERS-CoV S1 ELISA and IFA assay (12).”
BackgroundMethodPersistence of Antibodies against Middle East Respiratory Syndrome Coronavirus
Payne, D. C., Iblan, I., Rha, B., Alqasrawi, S., Haddadin, A., Al Nsour, M., Alsanouri, T., Ali, S. S., Harcourt, J., Miao, C., et al. (2016) · Emerging Infectious Diseases · doi:10.3201/eid2210.160706 · Cited by 201
“Recently, antibodies against MERS-CoV were found (by ELISA and IFA) in 9 healthcare workers in Saudi Arabia with symptomatic MERS-CoV infection at least 18 months after infection (3).”
Marklund, E., Leach, S., Axelsson, H., Nyström, K., Norder, H., Bemark, M., Angeletti, D., Lundgren, A., Nilsson, S., Andersson, L.-M., et al. (2020) · PLOS ONE · doi:10.1371/journal.pone.0241104 · Cited by 189
“Whilst all patients infected by SARS-CoV were found to develop IgG antibodies [4], some patients with mild symptoms of MERS-CoV failed to develop detectable levels of IgG [5].”
BackgroundDuthie, M. S., & Reed, S. G. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-020-11062-4 · Cited by 15
“, fleeting positivity and a lack of information relating to history of infection or immune status), but the rapid waning of antibody titers is a natural phenomenon common to coronavirus immunity also been reported after SARS-CoV-2 infection (Alshukairi et al. 2016; Callow et al. 1990; Ibarrondo et al. 2020; Long et al…”
BackgroundPiccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Metadata
- Authors
- Alshukairi, A. N., Khalid, I., Ahmed, W. A., Dada, A. M., Bayumi, D. T., Malic, L. S., Althawadi, S., Ignacio, K., Alsalmi, H. S., Al-Abdely, H. M., Wali, G. Y., Qushmaq, I. A., Alraddadi, B. M., & Perlman, S.
- Venue
- Emerging Infectious Diseases
- Published
- 2016-06
- Volume
- 22
- Issue
- 6
- ISSN
- 1080-6040 (ISSN-L)
- 1080-6059
- OpenAlex
- W2343747529
- Cited by
- 139
- References
- 2
- FWCI
- 7.84
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.